Table 2.
Patient characteristics at the registry baseline and exposure years by treatment.
| Non–Biologics, Total | Apremilast | Ciclosporin | ||||
|---|---|---|---|---|---|---|
| 8136 Patients | 763 Patients | 558 Patients | ||||
| 13,648 Exposure Years | 946 Exposure Years | 717 Exposure Years | ||||
| Mean (SD) | Median (Range) | Mean (SD) | Median (Range) | Mean (SD) | Median (Range) | |
| Female sex, n (%) | 3513 (43.2) | 361 (47.3) | 255 (45.7) | |||
| Age, years | 47.8 (15.0) | 48.0 (18.0–92.0) | 52.0 (15.6) | 52.0 (18.0–89.0) | 43.5 (14.4) | 43.0 (18.0–92.0) |
| Body mass index (BMI), kg/m2 | 28.5 (5.9) | 27.6 (14.7–67.3) | 29.0 (6.2) | 28.0 (15.9–60.6) | 27.7 (6.0) | 26.8 (15.9–63.3) |
| Duration of psoriasis, years | 15.9 (14.5) | 12.0 (0.0–76.0) | 20.0 (16.0) | 17.0 (0.0–76.0) | 15.3 (12.8) | 12.0 (0.0–68.0) |
| Nail psoriasis, n (%) | 3669 (45.1) ** | 389 (51.0) | 274 (49.1) | |||
| Psoriatic arthritis, n (%) | 2209 (27.2) ** | 289 (37.9) | 149 (26.7) | |||
| Multimorbid *, n (%) | 727 (8.9) ** | 120 (15.7) | 27 (4.8) | |||
| Psoriasis area and severity index (PASI) | 14.3 (9.6) | 12.4 (0.0–70.8) | 6.5 (2.3) | 7.0 (0.0–10.0) | 6.9 (2.1) | 7.0 (0.0–10.0) |
| Body surface area (BSA) | 23.1 (19.2) | 16.0 (0.0–100.0) | 21.9 (18.1) | 15.0 (0.0–95.5) | 23.1 (19.7) | 16.0 (0.0–100.0) |
| Dermatology life quality index (DLQI) | 11.1 (7.1) | 10.0 (0.0–30.0) | 11.1 (7.0) | 10.0 (0.0–30.0) | 12.1 (7.1) | 11.0 (0.0–30.0) |
| Fumaric Acid Esters | Methotrexate | Retinoids | ||||
| 4024 Patients | 3826 Patients | 203 Patients | ||||
| 5231 Exposure Years | 6874 Exposure Years | 333 Exposure Years | ||||
| Mean (SD) | Median (Range) | Mean (SD) | Median (Range) | Mean (SD) | Median (Range) | |
| Female sex, n (%) | 1691 (42.0) | 1621 (42.4) | 105 (51.7) | |||
| Age, years | 45.5 (15.4) | 45.0 (18.0–92.0) | 49.4 (13.7) | 50.0 (18.0–88.0) | 53.8 (14.4) | 55.0 (18.0–83.0) |
| BMI, kg/m2 | 28.2 (5.9) | 27.2 (14.7–63.0) | 28.9 (5.9) | 28.0 (15.4–67.3) | 28.2 (5.1) | 27.7 (17.6–46.3) |
| Duration of psoriasis, years | 14.3 (13.8) | 10.0 (0.0–68.0) | 17.1 (14.7) | 14.0 (0.0–76.0) | 13.4 (14.6) | 7.0 (0.0–53.0) |
| Nail psoriasis, n (%) | 1648 (41.0) | 1873 (49.0) | 99 (48.8) | |||
| Psoriatic arthritis, n (%) | 622 (15.5) | 1503 (39.3) | 38 (18.7) | |||
| Multimorbid *, n (%) | 286 (7.1) | 366 (9.6) | 27 (13.3) | |||
| PASI | 6.5 (2.2) | 7.0 (0.0–10.0) | 14.4 (10.2) | 12.4 (0.0–70.8) | 11.9 (9.5) | 10.0 (0.0–56.1) |
| BSA | 23.7 (18.8) | 18.0 (0.0–100.0) | 22.7 (19.4) | 15.0 (0.0–100.0) | 19.5 (20.3) | 12.0 (1.0–100.0) |
| DLQI | 11.0 (6.9) | 10.0 (0.0–30.0) | 11.3 (7.2) | 11.0 (0.0–30.0) | 11.2 (6.9) | 11.0 (0.0–30.0) |
Significant differences (p < 0.05) between non-biologics and biologics (Table 1) are marked with **. Other treatment groups were not tested against each other. The number of patients is not additive because patients may have received more than one treatment. * Patients with 3 or more different comorbidity groups are referred to as multimorbid.